Key result
MitraClip achieves ~75% 2-year overall survival in high-risk patients.
Why the study?
Data for long-term survival and preprocedural predictors of mortality after percutaneous mitral valve repair in high surgical risk patients are sporadic.
Cohort (n=136)
Favorable 2-year survival after MitraClip in high-risk patients; leaves open prospective validation of NYHA class, NT-proBNP, and age for refined selection.
OBJECTIVES: To evaluate long-term survival in high surgical risk patients undergoing percutaneous mitral valve repair (MVR) using the MitraClip(®) system and to identify preprocedural predictors of long-term mortality. BACKGROUND: Data for long-term survival and preprocedural predictors of mortality after percutaneous MVR in high surgical risk patients are sporadic. METHODS: From January 2009 to April 2013, 136 consecutive high surgical risk patients, with symptomatic moderate-to-severe or severe mitral regurgitation (MR), underwent percutaneous MVR using the MitraClip system. Cardiac and overall survival was determined at one and 2 years postprocedure. Univariate and multivariate analysis was performed to identify preprocedural predictors of long-term mortality. RESULTS: One year postprocedure, cardiac and overall survival was 86.7% and 84.6%, respectively and at 2 years cardiac and overall survival was 77.7% and 74.8%, respectively. In univariate analysis advanced age, lower body mass index, impaired renal function, elevated levels of log-N-terminal-pro-brain-natriuretic-peptide (log-NTproBNP), poor performance in functional tests (New York Heart Association (NYHA) class) and high logistic Euroscore (LES) and Society of Thoracic Surgeons (STS) score were identified as preprocedural predictors of long-term cardiac mortality. In multivariate analysis preoperative NYHA class III and IV, elevated levels of log-NTproBNP and advanced age predicted long-term cardiac mortality. CONCLUSIONS: Percutaneous MVR using the MitraClip system has favorable long-term survival rates in high surgical risk patients. Preprocedural NYHA functional class III and IV, elevated log-NTproBNP levels and advanced age predict higher long-term cardiac mortality and should be considered during patient selection.
No takes yet. Share an insight, caveat, or question.
Triantafyllis et al. (2015) conducted a cohort in Symptomatic moderate-to-severe or severe mitral regurgitation (n=136). Percutaneous mitral valve repair using the MitraClip system was evaluated on Cardiac and overall survival at 1 and 2 years postprocedure. Percutaneous mitral valve repair with MitraClip in high-risk patients resulted in 2-year cardiac and overall survival of 77.7% and 74.8%, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: